Published Healthcare & Pharmaceuticals Novel antibiotics We have developed lead BPL antagonist BPL199, which is active against Staphylococcus aureus BPL and Mycobacterium tuberculosis with > 44m-fold less selectivity for human BPL. By University of Adelaide
Published Medical Lugdunomycin Unique chemical structure: unique mechanism of action? Novel target: identification of additional compounds? By Leiden University
Do you have an innovative technology, product or service? Add your solution to the world’s most advanced open innovation platform and get seen by global corporations seeking new solutions – all free of charge.
